ATE442854T1 - Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung - Google Patents

Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung

Info

Publication number
ATE442854T1
ATE442854T1 AT05728461T AT05728461T ATE442854T1 AT E442854 T1 ATE442854 T1 AT E442854T1 AT 05728461 T AT05728461 T AT 05728461T AT 05728461 T AT05728461 T AT 05728461T AT E442854 T1 ATE442854 T1 AT E442854T1
Authority
AT
Austria
Prior art keywords
prevention
treatment
methylthioadenosine
autoimmune diseases
transplant rejection
Prior art date
Application number
AT05728461T
Other languages
English (en)
Inventor
Diaz Pablo Villoslada
Zaragoza Matias Avila
Bruna Beatriz Moreno
Izquierdo Fernando Corrales
Lasarte Carmen Berasain
Garcia-Trevijano Elena Ruiz
Original Assignee
Proyecto Biomedicina Cima Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proyecto Biomedicina Cima Sl filed Critical Proyecto Biomedicina Cima Sl
Application granted granted Critical
Publication of ATE442854T1 publication Critical patent/ATE442854T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT05728461T 2005-03-17 2005-03-17 Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung ATE442854T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES2005/000139 WO2006097547A1 (es) 2005-03-17 2005-03-17 Empleo de 5'-metiltioadenosina (mta) en la prevención y/o tratamiento de enfermedades autoinmunes y/o rechazo de transplantes

Publications (1)

Publication Number Publication Date
ATE442854T1 true ATE442854T1 (de) 2009-10-15

Family

ID=36991307

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05728461T ATE442854T1 (de) 2005-03-17 2005-03-17 Verwendung von 5'-methylthioadenosin zur prävention und/oder behandlung von autoimmunkrankheiten und/oder transplantatabstossung

Country Status (19)

Country Link
US (1) US7820637B2 (de)
EP (1) EP1891961B1 (de)
JP (1) JP2008533107A (de)
CN (1) CN101141970A (de)
AT (1) ATE442854T1 (de)
AU (1) AU2005329287B2 (de)
BR (1) BRPI0520129A2 (de)
CA (1) CA2601557A1 (de)
CY (1) CY1109539T1 (de)
DE (1) DE602005016729D1 (de)
DK (1) DK1891961T3 (de)
ES (1) ES2334924T3 (de)
HR (1) HRP20090646T1 (de)
MX (1) MX2007011327A (de)
PL (1) PL1891961T3 (de)
PT (1) PT1891961E (de)
RS (1) RS51122B (de)
SI (1) SI1891961T1 (de)
WO (1) WO2006097547A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
WO2010142827A1 (es) * 2009-06-11 2010-12-16 Proyecto De Biomedicina Cima, S. L. Propiedades neuroprotectoras de 5'-metiltioadenosina
WO2011054990A2 (es) * 2009-11-05 2011-05-12 Proyecto De Biomedicina Cima, S.L. Composiciones para la inhibición y/o bloqueo de la transición epitelial-mesenquimal
JP5801572B2 (ja) * 2011-03-03 2015-10-28 シーシーアイ株式会社 PPARγ活性化剤
CN105153042B (zh) * 2015-07-17 2017-11-24 四川大学 一种化合物及其在制备治疗可卡因成瘾的药物中的用途
JP2022526604A (ja) 2019-04-05 2022-05-25 プレリュード・セラピューティクス・インコーポレイテッド タンパク質アルギニンメチルトランスフェラーゼ5の選択的阻害剤
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114515294A (zh) 2022-02-25 2022-05-20 浙江中医药大学 5’-甲基硫代腺苷在制备肥胖抑制药物或保健品中的应用
CN117122689A (zh) * 2023-09-12 2023-11-28 四川省医学科学院·四川省人民医院 Mta在制备治疗急性葡萄膜炎药物中的应用
CN118141910B (zh) * 2024-04-03 2025-10-28 河北医科大学 甲基转移酶抑制剂作为呼吸道合胞病毒疫苗及过敏疫苗佐剂的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1193529B (it) * 1980-04-22 1988-07-08 Bioresearch Srl Derivati adenosinici ad attivita' antinfiammatoria ed analgesica e composizioni terapeutiche che li contengono come principio attivo
IT1227049B (it) * 1988-07-29 1991-03-14 Bioresearch Spa Impiego di derivati adenosinici per la preparazione di composizioni farmaceutiche aventi attivita' immunostimolante.
HUP0001186A3 (en) * 1996-10-16 2002-04-29 Icn Pharmaceuticals Inc Costa Purine l-nucleosides,analogs and pharmaceutical compositions thereof
BR9814820A (pt) * 1997-10-14 2000-10-03 Welfide Corp Compostos de piperazina e seu uso médico
TW466112B (en) 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
JP2001072660A (ja) * 1999-09-08 2001-03-21 Welfide Corp TNF−α産生抑制剤および/またはIL−10産生促進剤
PL357555A1 (en) * 2000-01-31 2004-07-26 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
WO2001066518A1 (en) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. φ-SUBSTITUTED PHENYL-PROSTAGLANDIN E-ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
WO2003028712A2 (en) 2001-09-28 2003-04-10 Universite Libre De Bruxelles Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
DE10207843A1 (de) * 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
IL148736A0 (en) * 2002-03-18 2002-09-12 Pharmos Corp Dexanabinol and dexanabinol analogs which regulate inflammation related genes

Also Published As

Publication number Publication date
EP1891961B1 (de) 2009-09-16
ES2334924T3 (es) 2010-03-17
DE602005016729D1 (de) 2009-10-29
CY1109539T1 (el) 2014-08-13
US20090042831A1 (en) 2009-02-12
CN101141970A (zh) 2008-03-12
US7820637B2 (en) 2010-10-26
PL1891961T3 (pl) 2010-02-26
CA2601557A1 (en) 2006-09-21
MX2007011327A (es) 2008-01-28
AU2005329287B2 (en) 2011-01-27
PT1891961E (pt) 2009-12-17
BRPI0520129A2 (pt) 2009-04-28
EP1891961A1 (de) 2008-02-27
AU2005329287A1 (en) 2006-09-21
DK1891961T3 (da) 2009-12-21
JP2008533107A (ja) 2008-08-21
RS51122B (sr) 2010-10-31
SI1891961T1 (sl) 2010-01-29
HRP20090646T1 (hr) 2010-01-31
WO2006097547A1 (es) 2006-09-21

Similar Documents

Publication Publication Date Title
CY1109539T1 (el) Χρηση 5'-μεθυλοθειοαδενοσινης (μτα) στην προληψη και/η θεραπεια αυτοανοσων νοσων και/η απορριψης μοσχευματων
DE60328486D1 (de) Zusammensetzungen und verfahren zur beschichtung medizinischer implantate
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
MX2007007032A (es) Compuestos de aminopirimidina y metodos de uso.
DK1594833T3 (da) 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE526991T1 (de) Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
MY144318A (en) Methods of treating hiv infection.
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
PA8583601A1 (es) Derivados de pirrolidona como inhibidores de maob
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
ATE493985T1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
ATE554753T1 (de) 2,2'-dithio-bis(ethansulfonat) für den einsatz zur hemmung paclitaxel-induzierter abnormer thermoesthesia
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
DE60327856D1 (de) Zusammensetzungen und verfahren zur hautbräunung
EP1663283A4 (de) Glutamin zur verwendung bei der behandlung von verletzungen
DE60111574D1 (de) Bisphosphonate-enthaltenden zusammensetzungen zur vorbeugung und/oder heilung von metabolischen knochenkrankheiten, verfahren zu ihren herstellung und benutzung dieser zusammensetzungen
DE60325496D1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
DE602004016126D1 (de) Aplidine zur behandlung von multiplem myelom
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1891961

Country of ref document: EP